Therapeutic Solutions International Spin Off Campbell Neurosciences Announces Novel Mechanistic Data on CampbellCell Stem Cell Therapy for Schizophrenia
Company Advances towards First Cell Therapy to Prevent Suicidal Associated Mental Illness
April 03, 2023 09:00 AM Eastern Daylight Time
ELK CITY, Idaho–(BUSINESS WIRE)–Therapeutic Solutions International (TSOI) Spin Off Company Campbell Neurosciences announced new data, covered by its previously filed patents, demonstrating that CampbellCell universal donor stem cells reduce symptoms of schizophrenia in an animal model through stimulation of immune modulation and production of the cytokine brain derived neurotrophic factors (BDNF).
In a series of experiments, it was demonstrated that CampbellCell administration resulted in upregulated production of the cytokine interleukin-4, which was needed to reduce the inflammatory cytokine interleukin-17 and to suppress schizophrenia development.
“Campbell Neurosciences is making substantial progress in development of a biomarker-based test for suicidal ideations which involves saliva based detection of inflammatory cytokines,” said Dr. Thomas Ichim, President, and CEO of Campbell Neurosciences. “In parallel we are developing the CampbellCell, which is a mesenchymal lineage stem cell that is optimized for production of neurotrophic factors, which are believed to help in patients suffering from brain inflammation, particularly the type of brain inflammation associated with schizophrenia.”
Schizophrenia is a significant cause of suicide and has been associated with multiple immunological abnormalities. Experiments such as the ones reported today suggest that suppression of brain inflammation may have a positive effect on schizophrenia treatment. The utilization of our CampbellCell for treatment of schizophrenia was also associated with modulation of several immune cells including M2 monocytes and natural killer T cells.
“We are extremely pleased with the rapid pace of progress at Campbell Neurosciences, which to my knowledge is the only company leveraging immunotherapy and regenerative medicine to address diagnosis and treatment of mental diseases,” said Timothy Dixon, President, and CEO of Therapeutic Solutions International. “I commend Dr. Ichim for his enormous contributions, including being inventor on over 300 issued and published patent applications. I am happy to see that the goal of Campbell Neurosciences, which is a world without suicide, is getting closer and closer to being accomplished.”
About Therapeutic Solutions International, Inc.
Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. The Company’s corporate website is www.therapeuticsolutionsint.com.
About Campbell Neurosciences, Inc.
Campbell Neurosciences is committed to establishing a biological basis for diagnosis and treatment of suicide and its causes, including Schizophrenia and other mental health disorders, thereby eliminating the stigma of the disease. The Company’s corporate website is www.campbellneurosciences.com.